Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Chronic Pharyngitis01:23

Chronic Pharyngitis

12.5K
Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
12.5K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

750
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
750
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

768
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
768
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

816
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
816
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

383
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
383
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

2.6K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

HemaSphere·2026
Same author

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

HemaSphere·2026
Same author

Chronic lymphocytic leukemia with <i>IGH</i>::<i>BCL3</i>-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape.

HemaSphere·2026
Same author

The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.

Leukemia·2026
Same author

Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

European journal of haematology·2026
Same author

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Leukemia & lymphoma·2026

Video Experimental Relacionado

Updated: Feb 14, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.5K

Leucemia linfocítica crónica

Michael Hallek1, Tait D Shanafelt2, Barbara Eichhorst1

  • 1Department of Internal Medicine, Center of Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany.

Lancet (London, England)
|February 26, 2018
PubMed
Resumen

Los avances recientes en la patogénesis de la leucemia linfocítica crónica (LLC) han producido nuevas herramientas de pronóstico y terapias dirigidas, mejorando los resultados de los pacientes. Esta revisión cubre el progreso y analiza las estrategias óptimas de manejo de la enfermedad.

Más Videos Relacionados

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.6K

Videos de Experimentos Relacionados

Last Updated: Feb 14, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.5K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.6K

Área de la Ciencia:

  • Hematología
  • En el campo de la oncología
  • Medicina Clínica

Sus antecedentes:

  • La leucemia linfocítica crónica (LLC) es la leucemia más prevalente en las naciones desarrolladas, generalmente diagnosticada a los 72 años.
  • Las decisiones de tratamiento para la leucemia linfocítica crónica se guían por los sistemas de estadificación Rai y Binet y la presencia de síntomas.
  • La quimioterapia y los anticuerpos monoclonales anti-CD20 representan el estándar de atención para muchos pacientes con CLL.

Objetivo del estudio:

  • Revisar los avances recientes en el manejo de la LLC.
  • Para resaltar nuevas herramientas de pronóstico y terapias dirigidas.
  • Identificar las cuestiones emergentes en el manejo óptimo de la enfermedad de CLL.

Principales métodos:

  • Revisión de la literatura científica reciente sobre la leucemia linfocítica crónica.
  • Análisis de nuevas herramientas de pronóstico y terapias dirigidas.
  • Discusión de las estrategias de tratamiento actuales y futuras.

Principales resultados:

  • Avances significativos en la comprensión de la patogénesis de la CLL.
  • Desarrollo de nuevas herramientas de pronóstico y terapias dirigidas (ibrutinib, idelalisib, venetoclax).
  • Mejora de los resultados clínicos para subgrupos específicos de pacientes con LLC.

Conclusiones:

  • Las terapias dirigidas han alterado el estándar de atención para ciertos pacientes con LLC.
  • La investigación en curso es crucial para refinar el manejo óptimo de la enfermedad.
  • Se necesitan más investigaciones para abordar nuevas cuestiones en el tratamiento de la LLC.